Chủng tộc/dân tộc và việc khởi động liệu pháp điều trị kháng virus hoạt động cao (HAART) trong một nhóm quân nhân nhiễm HIV
Tóm tắt
Từ khóa
#HAART #chủng tộc #dân tộc #HIV #liệu pháp dự phòng PCPTài liệu tham khảo
Palella FJ, Delaney KM, Moorman AC: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998, 338: 853-860. 10.1056/NEJM199803263381301
Palella FJ, Deloria-Knoll M, Chmiel JS: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003, 138: 620-626. 10.7326/0003-4819-138-8-200304150-00007
Gras L, Kesselring AM, Griffith JT: CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr. 2007, 45: 183-192. 10.1097/QAI.0b013e31804d685b
Moore RD, Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007, 44: 441-446. 10.1086/510746
Emery S, Neuhaus JA, Phillips AN: Major clinical outcomes in antiretroviral therapy in (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008, 197: 1133-1144.
Kitahata MM, Gange SJ, Abraham AG: Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009, 360: 1815-1826. 10.1056/NEJMoa0807252
Sterne JA, May M, Costagliola D: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009, 373: 1352-1363.
Turner BJ, Cunningham WE, Duan N: Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med. 2000, 160: 2614-2622. 10.1001/archinte.160.17.2614
Shapiro MF, Morton SC, McCaffrey DF: Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. J Am Med Assoc. 1999, 281: 2305-2315. 10.1001/jama.281.24.2305.
Gebo KA, Fleishman JA, Conviser R: Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005, 38: 96-103. 10.1097/00126334-200501010-00017
Easterbrook PJ, Phillips AN, Hill T: Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med. 2008, 9: 47-56. 10.1111/j.1468-1293.2008.00512.x
Cargill VA, Stone VE: HIV/AIDS: a minority health issue. Med Clin North Am. 2005, 89: 895-912. 10.1016/j.mcna.2005.03.005
Beach MC, Keruly J, Moore RD: Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV?. J Gen Intern Med. 2006, 21: 661-665. 10.1111/j.1525-1497.2006.00399.x
Anastos K, Schneider MF, Gange SJ: The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005, 39: 537-544.
Silverberg MJ, Wegner SA, Milazzo MJ: Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006, 20: 1531-1538. 10.1097/01.aids.0000237369.41617.0f
Hartzell JD, Spooner K, Howard R: Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr. 2007, 44: 411-416. 10.1097/QAI.0b013e31802f83a6
Weintrob AC, Grandits GA, Agan BK: Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr. 2009, 52: 574-580. 10.1097/QAI.0b013e3181b98537
Marconi VC, Grandits GA, Weintrob AC: Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military Natural History Study. AIDS Res Ther. 2010, 7: 14- 10.1186/1742-6405-7-14
Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Dep Health Hum Serv. 2008, 1: 139-Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 19 November 2009, Available at . Accessed 19 November 2009
Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992, 41: 1-19.
Lemly DC, Shepherd BE, Hulgan T: Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis. 2009, 199: 991-998. 10.1086/597124
Brodine SK, Starkey MJ, Shaffer RA: Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS. 2003, 17: 2521-2527. 10.1097/00002030-200311210-00016
Palacio H, Kahn JG, Richards TA, Morin SF: Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep. 2002, 117: 233-251. 10.1016/S0033-3549(04)50158-9
Cohen MH, Cook JA, Grey D: Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health. 2004, 94: 1147-1151. 10.2105/AJPH.94.7.1147
McNaghten AD, Hanson DL, Dworkin MS, Jones JL: Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2003, 32: 499-505. 10.1097/00126334-200304150-00006
Oramasionwu CU, Brown CM, Lawson KA: Differences in national antiretroviral prescribing patterns between black and white patients with HIV/AIDS, 1996-2006. South Med J. 2011, 104: 794-800. 10.1097/SMJ.0b013e318236c23a
King WD, Wong MD, Shapiro MF: Does racial concordance between HIV-positive patients and their physicians affect the time to receipt of protease inhibitors?. J Gen Intern Med. 2004, 19: 1146-1153. 10.1111/j.1525-1497.2004.30443.x
Osborn CY, Paasche-Orlow MK, Davis TC, Wolf MS: Health literacy: an overlooked factor in understanding HIV health disparities. Am J Prev Med. 2007, 33: 374-378. 10.1016/j.amepre.2007.07.022
Reynolds NR, Testa MA, Marc LG: Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav. 2004, 8: 141-150.
Jensen-Fangel S, Pedersen L, Pedersen C: The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis. 2002, 35: 1541-1548. 10.1086/344769
Losina E, Schackman BR, Sadownik SN: Racial and sex differences in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009, 49: 1570-1578. 10.1086/644772
Murphy K, Hoover DR, Shi Q: Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS. 2013, 27: 2413-2423. 10.1097/01.aids.0000432537.92958.73
Lazo M, Gange SJ, Wilson TE: Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007, 45: 1377-1385. 10.1086/522762
Bogart LM, Kelly JA, Catz SL, Sosman JM: Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000, 23: 396-404. 10.1097/00126334-200004150-00006
Himelhoch S, Brown CH, Walkup J: HIV patients with psychiatric disorders are less likely to discontinue HAART. AIDS. 2009, 23: 1735-1742. 10.1097/QAD.0b013e32832b428f
Maisels L, Steinberg J, Tobias C: An investigation of why eligible patients do not receive HAART. AIDS Patient Care STDs. 2001, 15: 185-191. 10.1089/10872910151133701